Navigation Links
Anemia Triples Risk of Local Recurrence in Breast Cancer Patients
Date:4/3/2008

No differences seen in overall survival, metastasis when chemo triggered low red blood cell count

THURSDAY, April 3 (HealthDay News) -- Breast cancer patients who develop anemia during chemotherapy face almost three times the risk of a recurrence in the same area of the affected breast, new research suggests.

The Austrian study was a re-analysis of information from a clinical trial that took place in the 1990s. Importantly, the findings also indicated that anemia did alter overall survival or significantly increase the risk of cancer occurring in a patient's other breast or spreading elsewhere in the body. Anemia, a common side effect of chemotherapy, is a low red blood cell count that can cause fatigue and reduced quality of life.

"This study is definitely not aimed at changing current practice," said study author Dr. Peter Dubsky, of the Medical University of Vienna. "This is a retrospective analysis that has yielded quite controversial data. The conclusion from our study is aimed at experimental and clinical oncologic research. Anemia is associated with a high likelihood of tumor hypoxia [too little oxygen in the blood]."

The chemotherapy used in the study was a combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). The problems of anemia and related local recurrence are probably not limited to just this form of chemotherapy, noted Dr. Douglas Yee, director of the University of Minnesota Cancer Center. "I think this effect would be seen with any chemotherapy."

CMF is no longer commonly used in the treatment of breast cancer and has been replaced by other forms of chemotherapy such as taxanes, added Dr. Barry C. Lembersky, a clinical associate professor of medicine at the University of Pittsburgh School of Medicine. Also, there is a trend in breast cancer treatment to use chemotherapy less often, he said.

"Nowadays, there is a more selective use of chemotherapy, which tends to be used when a tumor is not stimulated by estrogen, lymph nodes are involved, or the genetic/clinical profile is suited for chemotherapy," he explained.

In the Austrian study, CMF therapy was used as an additional treatment in 424 patients who were premenopausal and who underwent surgery as their main treatment for early-stage breast cancer. All had estrogen receptor-positive malignancies. The findings were published in the April 1 issue of Clinical Cancer Research.

The surgery was either a breast-conserving lumpectomy, which required additional radiation, or a modified radical mastectomy, for which radiation was optional. The radiation was given in the middle of chemotherapy treatment process, which is now an outdated method, Yee noted. "We tend not to do this kind of sandwich technique anymore," he explained.

After an average follow-up of 61 months, 39 local relapses occurred among the 424 women: 6.9 percent in patients without anemia and 19.5 percent in patients with anemia. The five-year rates of local relapse were 8.2 percent among patients without anemia and 19.6 percent among patients with anemia.

In addition to anemia, two other factors -- an older age at diagnosis and positive lymph node status -- significantly increased the risk of a local recurrence of breast cancer. According to an analysis of the range of factors examined in the study, patients with anemia had a 2.96-fold increased relative risk of a local recurrence.

Since the Austrian research was conducted, the treatment of anemia in breast cancer patients has become controversial, Lembersky noted.

"Erythropoietin-stimulating agents are indicated for use by the FDA [U.S. Food and Drug Administration] when red blood cell counts are too low," he said. "However, there is now controversy about their use due to the possible increase in tumor growth in breast cancer."

Dubsky agreed.

"I am sure you are aware of the recent pitfalls in the use of erythropoiesis-stimulating agents (ESAs)," he said. "Given this context, we should start discussing anemia more in the context of tumor hypoxia and look for targets that are distinct from erythropoiesis."

More information

Here's more on the treatment of early-stage breast cancer.



SOURCES: Peter Dubsky, M.D., Department of Surgery, Medical University of Vienna, Austria; Douglas Yee, M.D., director, University of Minnesota Cancer Center, Minneapolis; Barry C. Lembersky, M.D., clinical associate professor, medicine, University of Pittsburgh School of Medicine; April 1, 2008, Clinical Cancer Research


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Panel Supports Anemia Drugs for Cancer Patients
2. FDA Panel Weighs Safety of Anemia Drugs for Cancer Patients
3. UT Southwestern researchers investigate predictors for sickle-cell-anemia complications
4. Drugs used for cancer-associated anemia linked with increased risk of blood clots, death
5. Anemia Drugs for Cancer Patients Increase Death Risk
6. Anemia treatment may be a double-edged sword
7. FDA Reports New Risks Posed by Anemia Drugs
8. Modeling Simulation Predicts Potential Negative Impact on U.S. Blood Supply if ESA Use Limited for Chemotherapy-Induced Anemia
9. Evidence links anemia drugs with leukemic transformation in patients with primary myelofibrosis
10. New Kind of Stem Cells Reverse Sickle Cell Anemia
11. FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Anemia Triples Risk of Local Recurrence in Breast Cancer Patients
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the Root ... Orleans. This is a new, greatly improved version of the Doctor Referral teaming dataset ... by Fred Trotter and subsequently called the the “Doctor Referral Dataset” as released by ...
(Date:6/24/2017)... York (PRWEB) , ... June 24, 2017 , ... ... the Dental365 family. Located at 217 Portion Road in Lake Ronkonkoma, Dental365 offers ... evenings and weekends so that visits to the dentist fit into their patients’ ...
(Date:6/23/2017)... ... 23, 2017 , ... By scoring 100% for fiscal management and accountability, the ... online charity evaluator, Charity Navigator, validating ANRF's work as a top charity in America. ... Charity Navigator and earns ANRF a spot on their “ 10 Charities Worth Watching ...
(Date:6/23/2017)... ... 2017 , ... Military Connection friend and veteran advocate Micaela Bensko ... Atlantic lounge. , Bensko is no stranger to the plight of the disabled. ... life to supporting our wounded veterans. A world-class photographer, her riveting photos “The Wounds ...
(Date:6/23/2017)... ... 2017 , ... Georgia State University will host the First ... two-day conference is focused on advancing scientific knowledge about the aggressive triple negative ... racial breast cancer-related disparities. The conference theme is “Illuminating Actionable Biology.” , Conference ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. (ASX: ... on the design, manufacture, sale and distribution of the ... the progress of its commercial roll-out in ... in more than one hundred (100) medical institutions and ... AeroForm offers a needle-free alternative for women who choose ...
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ) today ... R. Goodwin , U.S. District Court Judge for the ... entered a case management order in MDL 2325, American ... (the "MDL") that includes a provision requiring plaintiffs in ... specific causation within one hundred twenty (120) days of ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly and ... that results from the Phase 3 MONARCH 2 ... & 6 inhibitor, in combination with fulvestrant, significantly ... fulvestrant alone in women with hormone-receptor-positive (HR+), human ... cancer who have relapsed or progressed after endocrine ...
Breaking Medicine Technology: